AstraZeneca (AZN) stock in focus as its antibody drug Imfinzi gains EU panel support for treating muscle-invasive bladder ...

AstraZeneca continues to impress me with the strong performances of its oncology, cardiovascular, and rare disease franchises ...

ZoomRx polled 50 experienced oncologists and hemato-oncologists about 20 cancer drugmakers, asking the doctors to rank the ...

As healthcare systems worldwide shift toward personalized treatment, biopharmaceuticals are gaining momentum for their ability to target disease mechanisms at the molecular level. The rapid ...

The “ Acute Myocardial Infarction Market Report ” by DelveInsight offers a robust analysis of market size, treatment ...

VANCOUVER, BRITISH COLUMBIA, CANADA, May 13, 2025 /EINPresswire.com/ -- Emergen Research's latest market research report, titled Global Anesthesia Drugs Market, provides estimated market size and ...

AstraZeneca recently announced its first-quarter earnings for 2025, showcasing strong financial performance with revenue rising to USD 13,588 million, up from the previous year. Despite this, the ...

AstraZeneca (AZN) CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on pharmaceuticals and said a more favorable corporate tax credit could motivate ...

A cancer drug from partners AstraZeneca and Daiichi Sankyo currently ... But the companies said Monday that the planned interim analysis showed the drug, Enhertu, led to a “highly statistically ...

AstraZeneca, one of the largest companies in Britain, was the biggest loser in the FTSE 100 yesterday, slumping 6.8pc, or 707p, to 9667p. It was followed by rival GSK, which tumbled 5.7 per cent ...